Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial

This study investigates whether the application of Hemopatch, a novel hemostatic patch, could prevent lymphatic leak after robotic-assisted radical prostatectomy (RARP) and bilateral pelvic lymph node dissection (BPLND). This is a prospective, single-center, phase III randomized controlled trial inv...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-09, Vol.14 (18), p.4476
Main Authors: Teoh, Jeremy Yuen-Chun, Liu, Alex Qinyang, Yuen, Violet Wai-Fan, Lai, Franco Pui-Tak, Yuen, Steffi Kar-Kei, Chan, Samson Yun-Sang, Wong, Julius Ho-Fai, Li, Joseph Kai-Man, Tam, Mandy Ho-Man, Chiu, Peter Ka-Fung, Yee, Samuel Chi-Hang, Ng, Chi-Fai
Format: Article
Language:English
Subjects:
Cancer
Catheters
Clinical trials
Collagen
Complications and side effects
Dissection
Lymph nodes
Lymphatic diseases
Lymphatic system
Metastasis
Methods
Nosocomial infections
Oncology, Experimental
Patients
Polyethylene glycol
Prevention
Prostate cancer
Prostatectomy
Proteins
Radiation therapy
Risk factors
Robotic surgery
Robotics
Surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study investigates whether the application of Hemopatch, a novel hemostatic patch, could prevent lymphatic leak after robotic-assisted radical prostatectomy (RARP) and bilateral pelvic lymph node dissection (BPLND). This is a prospective, single-center, phase III randomized controlled trial investigating the efficacy of Hemopatch in preventing lymphatic leak after RARP and BPLND. Participants were randomized to receive RARP and BPLND, with or without the use of Hemopatch, with an allocation ratio of 1:1. The primary outcome is the total drain output volume. The secondary outcomes include blood loss, operative time, lymph node yield, duration of drainage, drain output per day, hospital stay, transfusion and 30-day complications. A total of 32 patients were recruited in the study. The Hemopatch group had a significantly lower median total drain output than the control group (35 mL vs. 180 mL, p = 0.022) and a significantly lower drain output volume per day compared to the control group (35 mL/day vs. 89 mL/day, p = 0.038). There was no significant difference in the other secondary outcomes. In conclusion, the application of Hemopatch in RARP and BPLND could reduce the total drain output volume and the drain output volume per day. The use of Hemopatch should be considered to prevent lymphatic leakage after RARP and BPLND.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14184476